Posts

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

on

Summit Touts Updated HARMONi Data Showing Consistent Survival Benefit for Ivonescimab in Western NSCLC Patients

on

Summit reports two‑year survival data for Western patients, though context lacking

on

Nuvalent's cancer drug under FDA review, weeks after GSK closes $10.6B buyout

on

Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress – Eikon Therapeutics Clinical Pipeline Updates at ESMO 26 Congress in Madrid, Spain

on

Kelun's sac-TMT scores win in first-line PD-L1-negative NSCLC population missing from Merck's KEYTRUDA phase 3 program

on

AstraZeneca licenses EGFR lung cancer drug Zegfrovy from spinoff Dizal for up to $1.5B

on

NICE urges against future Lumakras reimbursement in UK – 2026 update

on

Pfizer'

on

Pfizer's first new ADC from Seagen acquisition fails Phase 3 NSCLC trial but may live on in earlier lines and combinations

on

GSK to Acquire Nuvalent and Its Two Cancer Drugs Under FDA Review for $10.6 Billion

on

ASCO 2026: Lilly’s Retevmo tied to dramatic outcomes in early‑stage RET fusion‑positive lung cancer

on

Eikon Therapeutics Presents Data on Clinical-Stage Programs at ASCO 2026

on

All eyes on Revolution, bispecific antibodies and more at ASCO26

on

Kelun‑Biotech to Present Two Registrational NSCLC Studies in Oral Session at ASCO 2026: ADC and RET Inhibitor Data in Metastatic NSCLC Patients

on

ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer

on

Gilead Loosens Ties with Arcus After TIGIT Drug Domvanalimab Fails Phase 3 Trial

on

AACR 2026: Path-IO AI Platform Predicts Immunotherapy Responses in Lung Cancer Patients

on

Dizal's Zegfrovy Achieves Phase 3 Success in First-Line NSCLC with EGFR Exon 20 Insertion, Challenging Chemotherapy Standard

on

Immutep's Phase 3 TACTI-004 Trial Failure Devastates Stock Price and Pipeline

on